Abstract:
PURPOSE: A composition containing a jujube extract and a tangerine pericarp extract containing naringin and hesperidin is provided which has an effect on prevention of adult diseases and cancer such as liver diseases, hypertension, arteriosclerosis, hyperlipidemia or the like when administered to animals. CONSTITUTION: This composition comprises a jujube extract and hesperidin, hesperetin, naringin, naringenin or a mixture thereof as flavonoid originated from a tangerine pericarp extract in a weight ratio of 1:0.001 to 1:0.1. For an example, 5kg jujube is extracted with 15L water at 100deg.C for 2hr two times, followed by filtering. The filtrate is then concentrated under reduced pressure to produce 2kg extract. And 500g tangerine is extracted with 5L ethanol at 60deg.C for 5 hr to produce 190g extract. The jujube extract and tangerine pericarp extract can be orally or parenterally administered at a dose of 0.1 to 5g, preferably 0.5 to 1g and 0.1 to 10g, preferably 0.5 to 2g/kg.weight.day respectively.
Abstract:
PURPOSE: A pharmaceutical composition and functional food and drink comprising neohesperid in dihydrochalcone are provided, for treating and preventing hyper lipidemia, arteriosclerosis, a liver disease and hyperglycemia. CONSTITUTION: The pharmaceutical composition comprises neohesperid in dihydrochalcone ineffective amount; and pharmaceutically acceptable carriers. The functional food or drink comprises 0.01-20 wt%, preferably 0.1-5 wt% of neohesperid in dihydrochalcone. Neohesperidin dihydrochalcone reduces the concentration of serum GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transminase) and a lipid in blood, inhibits HMG CoA (3-hydroxy-3-methylglutaryl coenzyme) being a reduction enzyme which relates to the biosynthesis of cholesterol and ACAT (acyl CoA; cholesterol-O-acyltransferase) which transforms cholesterol into cholesteryl ester, and inhibits the damage of a liver cell and the formation of a fatty liver. Also neohesperid in dihydrochalcone strongly inhibits the macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface, and reduces the concentration of blood sugar.
Abstract:
PURPOSE: A pharmaceutical composition and a functional food comprising bioflavonoid compounds are provided, for descending blood sugar. CONSTITUTION: The pharmaceutical composition comprises the bioflavonoid compounds represented by the formula 1 in effective amount; and pharmaceutically acceptable carriers. In the formula 1, R¬1 represents OH, rutinosyl or rhaminosyl group, R¬2 represents H, OH or rutinosyl group, R¬3 represents H or OH group, R¬4 represents OH or method group, and X represents a single bond or a double bond. The functional food comprises 0.01-50 wt%, preferably 0.05-10 wt% of the bioflavonoid compounds. The compounds of the formula 1 descends blood sugar, and therefore can be used for treating or preventing hyperglycemia.
Abstract:
본 발명은 감귤류 과피 추출물, 이로부터 분리 정제된 헤스페리딘 또는 나린진을 함유하는 심혈관 질환 예방 및 치료제 조성물에 관한 것으로, 감귤류 과피 추출물 및 이로부터 분리 정제된 헤스페리딘 및 나린진은 HMG-CoA 환원효소의 활성을 저해하여 혈중 콜레스테롤 농도를 저하시킴으로써 심장병, 동맥경화증 등의 심혈관 질환의 예방 및 치료제로 유용하게 사용될 수 있다.
Abstract:
본 발명은 헤스페리딘(hesperidin)을 포함하는 간 질환의 예방 및 치료용 조성물에 관한 것으로, 본 발명의 조성물은 의약용 및 식품용 조성물을 포함한다. 헤스페리딘은 동물에게 투여되었을 때 혈청 GOT(glutamate-oxaloacetate transaminase), GPT(glutamate-pyruvate transaminase) 및 γGTP(γ-glutamyl transpeptidase)의 농도를 강하시키므로 본 발명의 조성물은 각종 간 질환의 예방 및 치료제로서 유용하게 사용될 수 있다.
Abstract:
본 발명은 감귤류 과피의 추출액을 포함하는 아실 코에이: 콜레스테롤-o-아실트랜스퍼레이즈(acyl CoA: cholesterol-o-acyltransferase, ACAT) 활성 저해제 조성물에 관한 것으로, 본 발명의 조성물은 의약용 및 식품용 조성물을 포함한다. 본 발명의 조성물은 동물체내의 ACAT 활성을 저해하여 혈중 저밀도 지단백질(LDL) 콜레스테롤을 감소시키므로 각종 심혈관계 질환의 예방 및 치료제로서 유용하게 사용될 수 있다.
Abstract:
본 발명은 감귤류 과피 추출물, 이로부터 분리 정제된 헤스페리딘 또는 나린진을 함유하는 심혈관 질환 예방 및 치료제 조성물에 관한 것으로, 감귤류 과피 추출물 및 이로부터 분리 정제된 헤스페리딘 및 나린진은 HMG-CoA 환원효소의 활성을 저해하여 혈중 콜레스테롤 농도를 저하시킴으로써 심장병, 동맥경화증 등의 심혈관 질환의 예방 및 치료제로 유용하게 사용될 수 있다.
Abstract:
본 발명은 디오스민(diosmin)을 포함하는 동맥경화증 및 고지혈증의 예방 및 치료용 조성물에 관한 것으로, 디오스민은 동물에게 투여되었을 때 동맥내피에 대식세포-지질 복합체가 침착되는 것을 강력히 억제할 뿐만 아니라, ACAT 및 HMG-CoA 환원효소의 활성을 억제하고, 혈중 콜레스테롤 및 중성지질의 농도를 감소시키므로, 동맥경화증 및 고지혈증의 예방 및 치료제로서 유용하게 사용될 수 있다.
Abstract:
PURPOSE: Food composites including tannin or tannin-derived phenolics are provided to prevent and treat arteriosclerosis, hyperlipidemia and hepatic steatosis by dosing tannin, gallic acid or/and ellagic acid. CONSTITUTION: Tannin, gallic acid or/and ellagic acid is/are added to a food or a drink to prevent and treat arteriosclerosis. Tannin(C76H52O46) is extracted from acorns, persimmons and walnut shells. Gallic acid(C7H6O5) and ellagic acid(C14H6O8) are the decomposition products of tannin and have anticancer activities. The amount of the tannin-derived phenolics is from 0.01wt.% to 20wt.% according to the weight, age, gender, health status, diet, dosage time and method, excretory rate and disease level of patients.